Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the “Company”), a clinical-stage biotechnology company developing ...

Cash runway into Q3 2026 AFFIRM-1 Phase 3 clinical trial of BNC-210 in social anxiety disorder on track for topline readout in Q3 2025 α7 nicotinic acetylcholine receptor PAM MK-1167 partnered ...

What if nicotine—which we associate with addiction—actually holds the key to treating depression, ADHD, Alzheimer's, & ...

Neuphoria is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, “as needed ...

The molecular mechanism of cytokine regulation by the inflammatory reflex depends on signal transduction by the nicotinic acetylcholine receptor α7 subunit (α7nAChR). Administration of selective ...

Activation of the α7 nicotinic acetylcholine receptor may be therapeutically useful against acute lung injury by suppressing expression of pro-inflammatory genes.

Cash runway into Q3 2026 AFFIRM-1 Phase 3 clinical trial of BNC-210 in social anxiety disorder on track for topline readout in Q3 2025 α7 nicotinic acetylcholine receptor PAM MK-1167 partnered with ...

It appears that nicotine competes with spike proteins at the receptor sites ... body of research also suggests that SARS-CoV-2 may directly interfere with nicotinic acetylcholine receptors (nAChRs) – ...

Aβ can be produced within cells or taken up from extracellular sources through receptor binding and subsequent internalization. This leads to accumulation within endosomes, multivesicular bodies ...

Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to ...